Targeted-release budesonide therapy for IgA nephropathy

Targeted-release budesonide therapy for IgA nephropathy

Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2017-12, Vol.390 (10113), p.2625-2625
Hauptverfasser: Tsuda, Kenji, Tanimoto, Tetsuya, Mori, Jinichi, Kosugi, Kazuhiro, Komatsu, Tsunehiko
Format: Artikel
Sprache:eng
Schlagworte:
Drug therapy
Immunoglobulins
Kidney diseases
Steroids
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Bengt Fellström and colleagues (May 27, p 2117)1 report that the addition of a targeted-release formulation of budesonide (TRF-budesonide) to an optimised renin-angiotensin system (RAS) blockade reduced proteinuria in patients with IgA nephropathy. However, whether patients with proteinuria of 0·5-1·0 g/day, as were enrolled in this study, need further treatments in addition to RAS blockade therapy remains debatable.2,3
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(17)32145-1